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 Summary  
The aim of this thesis was to prepare composite nanomaterials for targeted delivery of 
radionuclides used for cancer diagnosis and therapy. Hydroxyapatite and TiO2 nanoparticles 
were used as vehicles for targeted delivery because of their suitable properties such as 
biocompatibility and radiochemical stability. Nanocomposites were prepared by precipitating 
phosphonate ligands or polyethylene glycol with nanoparticles. The role of the phosphonates 
is binding of radionuclides and stabilisation of nanoparticles.  
Prepared nanocomposites were labelled with 99mTc, a gamma emmiter used in tumor 
imaging and 223Ra, an alpha emmiter used in targeted alpha therapy.  
Phosphonic acids ethylenediamine tetra(methylenephosphonic) acid, 
propylenediamine tetra(methylenephosphonic) acid and 1,2-cyclohexyldiamine 
tetra(methylenephosphonic) acid were purified by ion exchange chromatography and used for 
preparation of nanocomposites. Besides mentioned ligands, methylene diphosphonic acid, 
etidronic acid, zoledronic acid, pamidronic acid and polyethylene glycol were used for 
experiments. 
For labelling with 99mTc, the best yields were obtained for 99mTc-CDTMP-HAp (89%), 
and 99mTc-PDTMP-HAp (93%) stabilised before labelling and 99mTc-MDP-HAp (92%) and 
99mTc-HEDP-HAp (89%) stabilised during their preparation. TiO2 nanocomposites all had 
yields >93%. 
Nanocomposites 223Ra-zoledronic acid-HAp stabilised after labelling showed the best 
yields (60%) for labelling with 223Ra. 
 
Key words: nanocomposites, hydroxyapatite, TiO2, phosphonic acids, 
99mTc, 223Ra 
  
Sažetak 
Cilj ovog rada bio je priprema kompozitnih nanomaterijala za ciljanu dostavu radionuklida 
koji se koriste u dijagnostici i terapiji raka. Nanočestice hidroksiapatita i TiO2 korištene su 
kao nosači za ciljanu dostavu zbog njihovih pogodnih svojstava, kao što su biokompatibilnost 
i radiokemijska stabilnost. Nanokompoziti su pripravljeni miješanjem fosfonatnih liganda ili 
polietilen glikola s nanočesticama. Uloga fosfonata je vezanje radionuklida i stabilizacija 
nanočestica. 
Pripremljeni nanokompoziti obilježeni su s 99mTc, radionuklidom koji emitira gama 
zračenje i koristi se u dijagnostici tumora te 223Ra, koji emitira alfa zračenje i koristi se u 
ciljanoj alfa terapiji. 
Fosfonske kiseline, etilendiamin tetra(metilenfosfonska) kiselina, propilendiamin 
tetra(metilenfosfonska) kiselina i 1,2-cikloheksildiamin tetra(metilenfosfonska) kiselina, 
pročišćene su ionsko izmjenjivačkom kromatografijom i korištene su za pripravu 
nanokompozita. Osim navedenih liganda, u eksperimentima su korištene i metilen 
difosfonska, etidronska, zoledronska i pamidronska kiselina te polietilen glikol. 
Za obilježavanje s 99mTc, najbolje iskorištenje dobiveno je za 99mTc-CDTMP-HAp 
(89%), i 99mTc-PDTMP-HAp (93%) stabilizirane prije označavanja i 99mTc-MDP-HAp (92%) 
i 99mTc-HEDP-HAp (89%) stabilizirane tijekom sinteze nanočestica. Svi nanokompoziti TiO2 
imali su iskorištenje veće od 93%. 
Nanokompoziti 223Ra-zoledronska kiselina-HAp stabilizirani nakon obilježavanja 
pokazali najbolje iskorištenje (60%) za označavanje s 223Ra. 
 
Ključne riječi: nanokompoziti, hidroksiapatit, TiO2, fosfonske kiseline, 99mTc, 223Ra 
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1. Introduction 
 
 2 
 
Cancer has been one of the major social and health concerns for the last ten decades. The 
World Health Organization (WHO) reported that cancers are among the leading causes of 
morbidity and mortality worldwide, with approximately 14 million new cases and 8,2 million 
cancer related deaths in 2012. It is expected that annual cancer cases will rise from 14 million 
in 2012. to 22 within the next 2 decades [1]. 
Cancer exhibits up-regulated cell growth, with an ability for tumor cells to invade and 
metastasize. Conventional anticancer drugs exhibit a lack of specificity, poor solubility and 
distribution, unfavorable pharmacokinetics and high tissue damage or toxicity. Cancer 
nanotechnology is expected to transform current treatment systems by providing more 
efficient cancer diagnostics and therapeutics. Customized nanoscale constructs can serve as 
targeted drug delivery vehicles capable of delivering large doses of radionuclide or 
chemotherapeutic agents into malignant cells while sparing normal tissues, greatly reducing 
the side-effects that usually accompany many current cancer therapies. 
The selection of potential radionuclides for tumor imaging and radionuclide radiotherapy 
involves the physical half-life, decay mode and the emission properties of the radionuclides. 
Gamma emitters with energy in the 150 keV range can be used for gamma imaging or single 
photon-emission tomography (SPECT), and high energy positron-emitters with energy of 511 
keV can be applied for positron-emission tomography (PET). For targeted radionuclide 
radiotherapy applications, high and low energy β emitters are ideal radioisotopes for the 
treatment of small to large clusters of tumor cells. The tissue penetration range (1-10 mm), 
and cross fire effect of β particles can kill tumor cells in close proximity to neovasculature. 
Alpha-emitters hold great promise as therapeutics for small cancer lesions and 
micrometastatic cancers due to their high linear energy transfer (LET, 80 keV/μm) and short 
range energy depositions with tissue penetration range of 50-100 μm [2]. 
Generally, the characteristics of a radiometal that make it advantageous for use in the 
production of a radiopharmaceutical include a stable oxidation state, a well-defined 
coordination chemistry in aqueous environment, and relatively fast complexation kinetics at 
physiological pH [3]. 
Technetium-99m is so far the most commonly used radionuclide in nuclear imaging. This 
is due to its highly interesting physical properties such as short half-life (6 h) and gamma 
photon emission of 140 keV, which are advantageous for both effective imaging and patient 
safety perspectives. Alpha emitting radionuclide 223Ra is suitable for use in radiotherapy of 
bone tumors and metastases due to its chemical similarity with Са. 
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Radionuclides have to be delivered to the targeted tissue by suitable vehicles. Since no 
chemical bond can withstand high recoil energies of daughter atoms, advanced labelling and 
targeting strategies have to be employed. This research was focused on hydroxyapatite and 
TiO2 nanoparticles stabilised with phosphonic acids which are the optimum compounds for 
delivering activity to bony tissues because of their high affinity for bone matrix 
hydroxyapatite. 
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2. Theoretical part 
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2.1. Nuclear medicine 
Nuclear medicine was developed in the 1930s due to the discovery of naturally occurring 
radioactivity by Becquerel, the invention of the cyclotron by E.O. Lawrence and the 
development of the controlled-fission reactor. Studies with naturally occurring radioactive 
isotopes in plants and animals, such as the classic work of de Hevesy, followed shortly after. 
In the 1950s, 131I was used to diagnose and treat thyroid cancer and disease. Soon afterwards, 
sodium iodine (Na131I) became the first radiopharmaceutical approved in 1951. for clinical 
use by the United States Food and Drug Administration (FDA). Today, tens of millions of 
nuclear medicine procedures using radiopharmaceuticals are performed each year in more 
than 10,000 hospitals worldwide. The most common radionuclide used in diagnosis is 99mTc, 
accounting for 80% of all nuclear medicine procedures. Nowadays, the field of nuclear 
medicine is evolving from anatomic toward molecular medicine, focusing more on the 
cellular and molecular pathways and mechanisms of disease [4]. 
The diagnosis and treatment of many tumors stills remains elusive and a major barrier to 
effective clinical outcomes. Cancer cells are known to possess unique characteristics of 
dividing and proliferating rapidly, resisting cell death or apoptosis and having devastating 
invasive potentials. Also, tumor cells have the ability to infiltrate surrounding normal tissues 
or penetrate into lymphatics and/or blood vessels enabling them to circulate and migrate to 
multiple distant sites or organs, forming secondary tumors. 
Most conventional treatments for management of cancers involve chemotherapy using 
low molecular weight anticancer agents that are systemically administered by the intravenous 
(i.v.) route. This intervention inherently lacks the ability to target tumors selectively. 
Low molecular weight anticancer compounds also suffer from short plasma circulation 
half-lives due to their rapid clearance through renal excretion. Also naked proteins, peptides, 
DNA, small interfering RNA (siRNA), and therapeutic molecules that are administered via 
the blood stream are generally labile and prone to degradation in the presence of serum or 
plasma components [5]. 
Nuclear medicine plays crucial role in the modern approach to cancer treatment by providing 
means to the following: 
 Determine the extent or severity of the disease, including metastases 
 Select the most effective therapy based on the unique biological characteristics of the 
patient and the molecular properties of a tumor 
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 Accurately assess the effectiveness of a treatment regimen 
 Adapt treatment plans quickly in response to changes in molecular and biochemical 
characteristics of the tumor 
 Assess disease progression 
 Identify recurrence of disease and help manage ongoing care [6] 
 
2.1.1. Nuclear imaging methods 
Diagnostic (or contrast) agents enhance visibility of specific tissues by increasing the signal to 
noise ratio relative to surrounding tissues and are generally optimized to provide a quick, 
high-fidelity snapshot of the living system. Molecular imaging modalities (Fig.1) include 
MRI, CT, US, optical imaging (bioluminescence and fluorescence), single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) [7]. 
 
 
Figure 1. Typical molecular imaging instruments and images representative of each modality 
[7]. 
SPECT forms a three-dimensional image of the distribution of gamma-emitting radiotracers 
injected into the body. One advantage of SPECT is that multiple probes labelled with separate 
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isotopes may be studied in parallel since each isotope might be associated with its unique γ 
spectrum [6]. 
PET, similar to SPECT, provides information about biochemical and physiological 
processes in the human body. For PET applications, positron-emitting radionuclides of first 
choice are 18F, 11C, 13N, and 15O. These elements are able to emit a positive electron from the 
nucleus. This positive electron, in turn, travels only a short distance through the tissue and 
interacts with a free or loosely bound negative electron. The outcome of this interaction is one 
positive electron and one negative electron annihilating each other, with the masses beeing 
converted into two photons, each consisting of 511 keV of energy and beeing given off in 
opposite directions (Fig.2).  
 
Figure 2. A schematic diagram showing positron emission during the decay process of a 
radionuclide [6]. 
 
The principal applied radionuclide for PET is Fluor-18 (18F) which is known for its ideal half-
life to manage (1,83 h). The development of the radiopharmaceutical [2-18F]-2-fluoro-2-
deoxyglucose (18FDG) has been so far an important progress for PET imaging in oncology. 
18FDG acts as a glucose analogue allowing the visualization of glucose consumption, a 
metabolic process being massively enhanced in many malignancies [8]. 
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2.1.2. Radionuclide therapy  
Radiopharmaceuticals are dosage forms consisting of one or two components, a carrier, a 
trace amount of radionuclide with a defined radiation type, or their combination. Therefore, 
the efficacy of a radiopharmaceutical is determined by its components. In tumor radiotherapy, 
the therapeutic effect is due to the tumoral absorption of alpha (α) or beta (β) radiation energy 
emitted by the radionuclide. The ideal radiopharmaceutical should convey the radioactive 
nuclide quantitatively to the tumor tissue,with no radiation reaching the normal tissues [2]. 
Table 1. Characteristics of potential radionuclides for nanotargeted tumor imaging [2]. 
Radionuclide Emission type Half-life Emax (γ), (keV) 
131I γ (81,2%), β 8,0 days 284, 364, 637 
67Ga γ 78,3 h 93, 184, 300, 393 
111In Auger, γ 67,2 h 171, 245 
123I Auger, γ 13,2 h 159 
99mTc γ 6,0 h 140 
18F Positron 1,83 h 511 
64Cu Positron 12,7 h 511 
 
Table 2. Characteristics of potential radionuclides for tumor radiotherapy [2]. 
Radionuclide Emission type Half-life Emax (MeV) Rmax (mean)1 Size of tumor cells2 
186Re β, γ (9,4%) 89,2 h 1,07 5 mm (0,9 mm) Intermediate clusters 
188Re β, γ (15,1%) 17 h 2,12 11 mm (2,4 mm) Large clusters 
177Lu β 161 h 0,49 1,6 mm (0,67 mm) Small clusters 
131I γ (81,2%) 8 d 0,28; 0,36; 0,64 2,0 mm Small clusters 
90Y β 64,1 h 2,28 12 mm (2,8 mm) Large clusters 
67Cu β 2,6 d 0,19 0,7 mm Small clusters 
225Ac α 10 d 5,83; 5,79; 5,79; 5,73 40-80 µm Single cells and small clusters 
211At α 7,2 h 5,87 60-80 µm Single cells and small clusters 
111In Auger, γ 67 h 0,42 2-500 nm Single cells 
1Radiation tumor tissue penetration maximum and mean range. 2Small, intermediate and large clusters correspond 
approximately to the intervals 106, 106-108, and 108-1010 tumor cells per cluster, respecitevely. 
The choice of radionuclide depends on its particular application. While radionuclides used for 
nuclear medicine imaging  (Table 1) emit gamma rays, which can penetrate deeply into the 
body, radionuclides used for therapy (Table 2) must emit radiation with a relatively short path 
length in order to deposit their energy locally and minimize the whole-body irradiation. There 
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are three types of particulate radiation of consequence for radionuclide therapy: beta particles, 
alpha particles, and Auger electrons [6].  
The major criteria for diagnostic use of radioisotopes are: 
 suitable physical properties, i.e. a high detection efficiency for the radionuclide, 
compatible with the lowest possible radiation dose to the patient 
 suitable biochemical properties, especially organ selectivity and comptability with the 
bio-kinetics. 
 
As far as physical properties are concerned, the half-life should be short (between a few 
minutes and a few hours) and the decay should occur preferably via IT, EC or β+ emission. 
Furthermore, the specific radioactivity of the final product should be rather high. In general, 
the diagnostic radioisotopes are classified into two groups, namely γ emitters (e.g. 67Ga, 111In, 
201Tl, etc.) and β+ emitters (e.g. 15O, 18F, etc.). If the radioisotope emits a single γ ray, SPECT 
can be used; in the case of β+ emitters, PET is very advantageous. Because of its quantitative 
nature, rapidity and higher resolution, PET is superior to SPECT [9]. 
One of the main pharmacological characteristics of diagnostic RPS 
(radiopharmaceutical substances) is the high ratio of activity accumulated per g of tumor to 
the activity taken up per g of soft tissue (the differential accumulation level). The blood 
elimination time must be short for high values of the ratio to be obtained, and the rate of 
accumulation of RPS in the lesion site must be maximal. On the other hand, the retention time 
of the labelled agent in blood should be optimal for reaching the receptor sites of tumors and 
the greatest level of accumulation in affected tissue. Furthermore, the RPS must be rapidly 
excreted from the body with urine to avoid accumulation in the gastrointestinal tract. This is 
of particular importance for therapeutic RPS, as excretion via the hepatobiliary system often 
leads to radionuclide accumulation in the gastrointestinal tract, leading to increased dose loads 
on the abdominal organs [10]. 
Biological targeting molecules of radiopharmaceuticals range from antibodies to 
antibody fragments, proteins, peptides and nucleic acids. More recently, a new type of 
molecules, namely nanoparticles or nanocarriers, has entered the radiopharmaceuticals area. 
Target specific nanoparticle radiopharmaceuticals can have a higher number of targeting 
molecules and radionuclides per particle [4]. Nanoparticles based on lipid- and polymer- 
formulations are developed as potential drug delivery agents [11], for example copolymers of 
N-isopropylmethacrylamide [12] which hydrophobically entrapped the therapeutic 
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radionuclide, 64Cu. Another approach for targeted delivery of radionuclides is using magnetic 
forces to target and hold magnetic nanoparticles in vivo at anatomical sites with restricted 
access [13, 14].  
 
2.1.2.1. Radioimmunotherapy 
Radioimmunotherapy (RIT) combines the advantages of radiation therapy and specific 
immunotherapy using mAbs. The antibody serves primarily as a delivery vehicle of radiation 
and has no significant effect on the function. The therapeutic effect is achieved by tissue 
absorption of the energies from continuous, low-dose radiation emitted from the radionuclides 
tagged to mAbs.  
The exact choice of radionuclide used for RIT depends on the radiation characteristics 
of the nuclide, the radiolabeling chemistry, and the type of malignancy or cells targeted. Beta 
emitters, because of their lower energy and longer path length, are more suitable for targeting 
bulky, solid tumors, whereas alpha emitters and Auger emitters, with their high LET and 
short-distance energy deposition, are better suited for targeting single cells, as in 
micrometastatic disease, blood borne malignancies, and locoregional applications [6]. The 
range of different emitters is shown in Figure 3. 
 
 
Figure 3. Schematic diagram of tumor tissue penetration range of internal radiotherapy by 
Auger electron (0,1–2 keV, <1 μm), α (5–8MeV, 50–80 μm range), and β- (0,1–2,2MeV, 1-10 
mm range ) radiation emitters [2]. 
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2.1.2.2. TAT targeted alpha particle therapy 
The effectiveness of targeted alpha therapy (TAT) can be explained by the properties of α 
particles. Alpha particles are helium nuclei ~8,000 times larger than β− particles (electrons). 
When emitted from radionuclides that decay via an α decay pathway, they release enormous 
amounts of energy over a very short distance. Typically, the range of α particles in tissue is 
50–100 μm and they have high linear energy transfer (LET) with a mean energy deposition of 
100 keV/μm, providing a more specific tumor cell killing ability without damage to the 
surrounding normal tissues than β- emitters (Fig.4). 
 
 
Figure 4. (a) Short path length of α particles, in the range of a few cell diameters, compared 
with (b) the longer path length of β particles [15]. 
Importantly, this high linear energy transfer (high-LET) radiation is not dependent on active 
cell proliferation or oxygenation, and the resulting DNA damage caused by α-particles is 
much more difficult to repair than that of β-. Radiation induces single- and doublestranded 
DNA break, causes apoptosis, and initiates overexpression of p53, leading to delays in the G1 
phase of the cell cycle. Death of cells exposed to α-particles occurs only when the particles 
traverse the nucleus; high concentrations of α-particles directed at the cytoplasm have no 
effect on cell proliferation [16]. 
Due to these properties, the majority of pre-clinical and clinical trials have 
demonstrated that α emitters such as 225Ac, 211At, 212Bi, 213Bi, 212Pb, 223Ra, and 227Th are ideal 
for treatment of smaller tumor burdens, micrometastatic disease, and disseminated disease.  
Even though these α emitters have favorable properties, the development of TAT has 
been limited by high costs, unresolved chemistry, and limited availability of the radionuclides. 
To overcome these limitations, more potent isotopes, additional sources, and more efficient 
isotope production methods should be addressed. Furthermore, better chelation and labelling 
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methods with improvements of isotope delivery, targeting vehicles, molecular targets, and 
identification of appropriate clinical applications are still required [17, 18].Bone metastasis 
cause severe pain, so there have been many attempts to develop curative treatment regimens. 
Beta emitting radiopharmaceuticals for bone targeting, such as 89Sr chloride, have been used 
clinically for treatment of bone pain. Although β emitters relieve bone pain associated with 
metastatic lesions in the skeleton, bone marrow toxicity limits use of high dose radiations to 
prevent tumor progression due to the long radiation range of β particles. To overcome this 
drawback, clinical use of several low energy α emitters, including 153Sm and 186Re, and the 
conversion electron emitter 117mSn, have been examined. Among these radionuclides, 153Sm 
complexed with ethylenediamine tetra(methylenephosphonic) acid (EDTMP), has been 
approved for use in palliation of bone pain by the U.S. FDA. Reduction of bone marrow 
exposure can be achieved due to the short range of α particles. A comparative study using 
bisphosphonates labelled with α emitting 211At and β emitting 131I indicated that the bone 
surface-to-bone marrow ratio was threefold higher with 211At than with 131I [19]. 
Bismuth-213, an α emitter with a half-life of 46 min, has shown to be effective in 
preclinical as well as in clinical applications, for example, glioma therapy [20] and  treatment 
of larger neuroendocrine tumours with  213Bi-DOTATATE [21]. 
Another point to be considered when the two forms of RIT (α and β) are compared is 
the dosimetry. The variation of α particle energy loss in matter is stochastic, necessitating the 
use of specific microdosimetric methods such as Monte Carlo calculation or analytical 
methods. These methods make it possible to calculate probability densities of specific energy 
(energy deposited in the targeted cellular volume and more often the cell nucleus), equivalent 
to the absorbed dose [15]. 
 
2.2. Targeted drug delivery  
Radiolabelled nanocarriers can be designed and used for cancer diagnostic and therapeutic 
purposes when tagged with appropriate radionuclides. Conventional anticancer drugs exhibit a 
lack of specificity, poor solubility and distribution, unfavorable pharmacokinetics and high 
tissue damage or toxicity. Targeted drug delivery systems such as passive and active targeting 
nanocarriers (Fig.5), with diameters ranging from 10-100 nm have been developed to improve 
the biodistribution, pharmacological, therapeutic and toxicity properties of agents used in 
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cancer diagnostics and therapeutics. One of the major challenges is to design a nanocarrier 
with less immunotoxic effect and to avoid biological barriers in the body such as to reduce 
delivered diagnostic and therapeutic agent uptake in the reticuloendothelial system (RES) [2]. 
 
 
Figure 5. Schematic representation of passive (A, B) and active (C, D) targeting 
nanoliposome encapsulated with radionuclides (A, C) and co-delivery of 
radiochemotherapeutics (B, D) [2]. 
 
As a platform, nanoparticles are wellsuited for developing targeted contrast agents, because:   
 they have a surface, which can be functionalized with one or more targeting molecules 
at a wide range of densities;  
 their plasma circulation time can be tuned over several orders of magnitude based on 
their physico-chemical properties;  
 contrast agents and drugs can be included at predetermined ratios either in the interior 
or on the surface.  
Nanoparticles can be made from a number of materials including proteins, peptides, polymers, 
lipids, metals and metal oxides, and carbon. The most relevant nanoparticle structures include 
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drug conjugates and complexes, dendrimers, vesicles, micelles, core–shell structures, 
microbubbles, and carbon nanotubes, which can all be functionalized with a targeting moiety, 
therapeutic, and contrast agent [7]. 
 
2.2.1. Radiolabelled nanocarriers 
Current progress in nanomedicine has exploited the possibility of designing tumor-targeted 
nanocarriers being able to deliver radionuclide payloads in a site or molecular selective 
manner to improve the efficacy and safety of cancer imaging and therapy. Radionuclides of 
auger electron, α, β, and γ radiation emitters have been surface-bioconjugated or after-loaded 
in nanoparticles to improve the efficacy and reduce the toxicity of cancer imaging and therapy 
in preclinical and clinical studies [2]. 
An ideal TNP (targeted nanoparticle) may have molecular targeting that can be imaged 
during its circulation in the body. Upon reaching its destination, it may have targeting 
moieties that associate with cellsurface receptors, internalize into the cytosol, target the 
intracellular target if necessary, and release the active therapeutic [7]. 
There are five approaches generally used for labelling or encapsulating radionuclides on 
nanocarriers:  
 Labelling nanocarriers by encapsulation during preparation;  
 nanocarrier surface labelling after preparation;  
 nanocarrier surface labelling of bioconjugates after preparation;  
 incorporation into the lipid bilayer after preparation;  
 after-loading of the aqueous phase of the nanocarriers after preparation. [2] 
 
There are three generations of nanocarriers developed: (i) the first generation of nanocarriers 
(passive targeting) which are rapidly trapped in the reticuloendothelial system (RES) organs 
(e.g., liver and/or spleen), (ii) the second generation of sterically stabilised PEGylated 
nanocarriers (passive targeting), which can evade the RES of the liver and spleen, enjoys a 
prolonged circulation in the blood and allows for passive targeting through the enhanced 
permeability and retention (EPR) effect in leaky tumor tissues, and (iii) the third generation of 
nanocarriers with a bioconjugated surface modification of the nanoparticles using specific 
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antibodies or peptides to actively target specific tumors or tissues through molecular 
interaction or affinity (active targeting). 
The main disadvantage of radionuclides is that no chelator or other type of labelled 
molecule can withhold the recoil energy of daughter hot atoms generated in such decays. 
Every hot daughter atom is thus immediately released from the carrier molecule and may 
cause severe damage to healthy tissues in vivo, particularly when applied systemically. Some 
nano-size engineered constructs are at least partially able to retain recoiled atoms and ensure 
proper therapeutical dose targeting due to their physical and chemical properties [22]. 
The selection of a proper radionuclide system may partially eliminate the problem of 
recoils release, when very short half-life values of daughter nuclei in a cascade (ns - μs - s) do 
not allow significant spread of activity from the location of the mother nuclide. The drawback 
of recoils release however leads to advanced design of novel radionuclide carriers based on 
nanomaterials. 
Released kinetic energy in the decay is distributed among the decay products 
following their masses according to the law of momentum conservation. Recoil energy 
released in the alpha particle decay can be in raw estimation expressed by the approximate 
relation (1): 
 
                                               𝐸𝑟 = 𝐸𝛼  
𝑚𝛼
𝑀𝑋
                                                       (1) 
Where the 𝐸𝑟 is the recoil energy of a daughter atom, 𝐸𝛼 the energy of released alpha particle, 
𝑚𝛼 is the rest mass of emitted alpha particle, and 𝑀𝑋 is mass of the daughter hot atom. Part of 
the recoil energy may be converted to translational energy of the remaining molecule or 
consumed for its dissociation. Chemical bond strength ranges typically in the order of 
magnitude of 1-10 eV, while kinetic energy of daughter hot atom usually reaches ≈ 100 keV 
in case of alpha particle decays. This is several orders of magnitude higher, compared to the 
energy of any chemical bond. On the other hand, to stabilise such hot atom in a molecular 
structure, to completely loose its energy (e.g. by inelastic scattering, ionization, excitation, 
etc.), it must hit several thousands of chemical bonds in e.g. a crystallite structure or in a 
polymer.  
Another important parameter is the recoils charge that may cause additional damage 
via electronic interaction with the nanoconstructs. For example, the recoils of 223Ra produced 
in 227Th decay reach the charge values of up to 40+. These supercharged hot atoms finally 
neutralize via interactions with their surroundings, while they ionize and excite molecules 
 16 
 
along their path and release most of their energy at the end of their path, around the Bragg 
peak. 
The elimination of recoils release from nanoconstructs in vivo could be generally achieved by 
three approaches. Firstly, the recoil energy is gradually attenuated in the intrinsic 
nanoconstruct material (“stopping by size”). Secondly, the final stabilisation of thermalized 
hot atom is achieved in a depot of multiple functional groups surrounding its track carried by 
several thousands of nanoconstructs (“stopping by depot”). In this case, the hot atom 
originating from one nanoconstruct after passing several other nanoconstruct units loses its 
energy and is finally stabilised in another nanoconstruct of the depot. To promote the trapping 
ability, the surface of the nanoconstruct is typically covered by many functionalities capable 
of catching such atom (e.g. functional groups, structural cavities, etc.). Finally, the third 
approach is performed only by the selection of a radionuclide system with appropriate decay 
parameters (“stopping by time”). All the approaches mentioned can be combined together, so 
the overall release of daughter recoils is almost insignificant. Another highly important issue 
is proper targeting of the nanocontructs. It could be achieved similarly as for multimodal 
constructs used mainly for imaging. The elimination of the uptake of nanoconstructs in RES 
could be achieved by proper surface coating and advanced drug-delivery systems [22]. 
 
2.2.2. Labelling of nanoparticles 
A very powerful and sensitive method to determine the in vivo behavior of NPs relies on 
radiolabelling and subsequent detection with single photon emission computed tomography 
(SPECT) or positron emission tomography (PET). Radiolabelling of NPs follows essentially 
two strategies; an “extrinsic” one in which potent, NP surface-bound chelators such as 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or 1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA), are directly labelled with 64Cu or 68Ga. Alternatively, complexes 
with bifunctional chelators are subsequently coated to the NP surface. In the “intrinsic” 
approach, the radiolabel is an integral part of the NP and no additional chelators are required 
[23]. 
In many cases, proton irradiation of nanoparticles allows radiolabelling by 
transmutation of a tiny fraction of their constituent atoms into radionuclides. However, not all 
types of nanoparticles offer nuclear reactions leading to radionuclides with adequate 
radiotracer properties [24]. 
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There are approximately 100 α emitting radionuclides (essentially heavy isotopes with 
an atomic number ≥82), but only a small number of them are available for clinical use. 
The majority of these α emitting radionuclides are produced in nuclear reactors; only a few 
are cyclotron products. In the case of radionuclides with a short physical half-life (such as 
bismuth-213), the duration of elution and compound purification must be short enough to 
obtain a radiopharmaceutical of good radiochemical quality and purity. The selection of α 
emitting radionuclides also has to take into account daughter products which could be 
metabolised in a different way than the parent [15]. 
An example of radionuclide production is the separation of 99Mo from 235UAl3 -alloy. 
The chemically separated 99Mo is used to prepare a generator system. This consists of loading 
the 99Mo activity on an Al2O3 column and milking off the decay product 
99mTc periodically by 
elution with saline. The 99Mo/99mTc generator is the most commonly used system in 
diagnostic nuclear medicine. Due to the ideal imaging properties of 99mTc with SPECT, about 
80% of all nuclear medical procedures are performed worldwide with it. The generator form 
makes the availability of 99mTc easy; its specific radioactivity is very high. The product is 
used directly for labelling biomolecules [9]. 
Alpha emitting radionuclides 224Ra and 223Ra are the most suitable radium isotopes for 
use in radiotherapy of bone tumors and metastases owing to their chemical similarity with Са. 
Radium-224 is used as a starting radionuclide in generators for production and 
medicobiological studies of 212Pb/212Bi, and also for treatment of Bechterew’s disease and 
skeletal tuberculosis. The main drawback of using 224Ra in nuclear medicine is production of 
a relatively long-lived gaseous daughter radionuclide, 220Rn (Т1/2=55,6 s), and, as a 
consequence, possible redistribution of the decay products in a living body. Furthermore, in 
the radioactive decay chain of 224Ra, there is 208Tl (3,1 min) emitting hard (2,6 MeV) γ 
radiation. 
The use of 223Ra in nuclear medicine is preferable compared to 224Ra because the 
daughter radionuclide of 223Ra, gaseous 219Rn (3,9 s), has a shorter half-life, so the decay 
products are mainly localized in the vicinity of the parent radionuclide. The total energy of α 
particles emitted in the course of the decay of 223Ra and its daughter products is ~27 MeV. 
Relatively long halflife of 223Ra (11,4 days) allows centralized production of 
radiopharmaceuticals and their delivery to various institutions remote from the production 
site. 
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The first radiopharmaceutical, Alpharadin, based on 223RaCl2, passed preclinical and 
clinical tests and in 2013. it was approved by the FDA (US Food and Drug Administration) 
for clinical use in the form of Xofigo commercial product. 
There are several types of radioisotope generators for production of short-lived α 
emitters and their separation from parent radionuclides, differing in the separation method 
used: ion exchange, extraction, distillation, etc. Today, ion-exchange and extraction-
chromatographic generators seem to be the most efficient and the safest because of their 
simple design, radiation safety, possibility of automating the separation of highly radioactive 
elements, and convenience of transportation. The parent radionuclide in such generators is 
sorbed and firmly retained on a chromatographic column packed with an appropriate sorbent, 
and the short-lived daughter radionuclide is eluted in the batch or continuous mode 
(depending on the half-life) with an appropriate eluent.  
For production of 223Ra, extraction-chromatographic 227Ac/223Ra generator, ion-
exchange 227Ас/227Th/223Ra generator and extraction 227Ас/223Ra generator can be used [25]. 
 
2.3. Components of composite nanomaterials 
Nanomaterials have recently been envisioned as carriers for radioisotopes in targeted 
radioimmunotherapy (RIT), targeted alpha therapy (TAT), and medical diagnostic imaging. 
This approach aims to overcome the global radiotoxicity of parent radionuclides and 
associated daughters, one of the main limitations of TAT. Inorganic nanomaterials are of 
interest as carriers because of their characteristic size-shape dependent properties, stable 
crystalline structures, and functionalizable surfaces [26]. 
The ideal attributes of microspheres or particulates for use as carriers of radionuclides for 
intra-arterial therapy are biocompatibility, biodegradability, ease of radiolabelling and high 
radiochemical stability of the labelled products to resist the possible leaching of radionuclide 
in vivo [27]. 
2.3.1. Titanium dioxide 
Titanium dioxide (TiO2) has a great number of applications due to its strong oxidizing power 
of the photogenerated holes, chemical inertness, non-toxicity, low cost, high refractive index 
and other advantageous surface properties. It is used in as a white pigment in paints, plastics, 
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paper and cosmetic products which represent the major end-use sectors of TiO2 [28]. 
Nanoparticulate TiO2, one of the most prevalent nanoparticle types, is produced in large-scale 
industrial processes for a wide range of applications.  
A recent study [29] presents three different options for radiolabelling of commercial 
TiO2 nanoparticles for particle detection, localization, and tracing under various experimental 
conditions. The limits for detection of TiO2 nanoparticles in concentrations as low as 0,5 ng/L 
could be realized in complex systems without the necessity of intense sample purification or 
pretreatment. 
 
2.3.2. Hydroxyapatite 
Hydroxyapatite (Ca10(PO4)6(OH)2, HAp) is a major mineral component in animals and 
humans and is widely studied due to its excellent biocompatibility, bioactivity and similarity 
in chemical composition with human bone tissues. As such, it is utilized in many biomedical 
applications such as orthopaedic implants, sustained drug release systems and as an adsorbent 
in column chromatography for purification and separation of nucleic acids and proteins [30]. 
A wide range of applications for HAp is possible because its properties can be tailored by 
controlling its composition, for example by substitution in the crystal structure, particle size 
and morphology prior to usage. 
 
Figure 6. Hydroxyapatite crystal structure. 
HAp particles get converted to Ca2+ and PO4
3- ions by natural metabolic process and 
eliminated over a period of 6 weeks, thereby ensuring excellent biocompatibility. Moreover, 
HAp particles can be easily tagged with lanthanide radioisotopes, resulting in highly stable 
radiolabelled preparations owing to the high chemical affinity of PO4
3- for the Ln3+ ions [27]. 
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Radioisotopes can be conjugated to HAp crystals using various linkers and chemical 
modifications of the particle surfaces. In 2007., Ong [31] reported that HAp nanoparticles can 
easily and rapidly (within 15 min) be loaded with drugs or radioisotopes by exploiting the 
high-affinity interaction between HAp and polyphosphonates. There are two main reasons for 
exploiting this interaction for drug or isotope loading on the HApNPs. First, it eliminates the 
need for surface chemical modifications of the HApNPs and second, various phosphonates are 
already used routinely in the clinic for treatment of a variety of diseases or as imaging agents 
[31]. 
 
2.3.3. Phosphonic acids 
Metastatic lesions of bones are among the most common complications of solid tumors such 
as breast, prostate, and lung tumors. Bone metastases in most of these patients lead to the 
development of a number of complications: bone pain, pathological fractures, and 
hypercalcemia, resulting in an overall deterioration in patients’ quality of life. 
Phosphonic acids and their salts are optimum compounds for delivering activity to 
bony tissues. This is a class of drugs, created on the basis of inorganic pyrophosphates in 
which the oxygen atom in the pyrophosphate molecule (P-O-P) is substituted with a carbon 
atom (P-C-P). While pyrophosphate is subject to hydrolysis by phosphatases, phosphonates 
are enzyme-resistant. These agents have affinity for bone matrix hydroxyapatite and show 
selective accumulation in zones with increased mineralization requirements, especially in 
metastatic and inflammatory-destructive foci.  
Phosphonates can have direct effects on tumor cells, stimulating apoptosis, inhibiting 
angiogenesis and matrix metalloproteases, decreasing tumor cell adhesion, and decreasing 
vascular endothelial growth factor levels. Multidentate polyaminophosphonic acids are widely 
used to create stable complex compounds with a variety of radionuclides, including 
lanthanoids. Among these are ethylenediamine tetra(methylenephosphonic) acid (EDTMP), 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonic) acid (DOTMP), 
propylenediamine tetra(methylenephosphonic) acid (PDTMP), diethylenetriaminopentakis- 
(methylphosphonic) acid (PPA), and others. Lexidronam, (153Sm-EDTMP) has undergone 
clinical trials and has been approved for clinical use. Depending on the use of the agent, 
radioactive labels are radionuclides such as 99mTc, 68Ga, 153Sm, 166Ho, 188Re, 177Lu, 170Tm, 
90Y, 227Th, 228Ac, 212Bi, and others. Technetium-99m is widely used in radionuclide diagnosis, 
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because of its unique nuclear physics and chemical properties. 99mTc has an optimum halflife 
(6 h) and γ quantum energy (140 keV).  
Gallium-68 is a potential radionuclide for creating radiopharmaceuticals for diagnosis 
of metastatic bone lesions by positron emission tomography (PET) using phosphonates as 
carrier molecules. The isotope 68Ga has optimum nuclear physics properties (T1/2 = 68 min, β+ 
= 89%, E+β max = 1.9 MeV). A great advantage of 
68Ga is that it can be prepared using a 
commercially available 68Ge/68Ga generator. 
The selective accumulation of radionuclides in bony tissue is explained by the following 
mechanisms of adsorption of diphosphonates labelled with radioactive isotopes by 
hydroxyapatites [(Ca10(PO4)6(OH)2]: 
 Adsorption of alkali-substituted elements (for example, 89Sr(II)) by exchange for 
calcium ions in bone tissue; 
 Interaction of charged three- and four-valent cations with hydroxyapatites to form 
insoluble phosphates or hydroxides, which attach tightly to the mineral components of 
bone tissue. This mechanism applies to the adsorption of 153Sm(III), 166Ho(III), and 
117mSn(III), forming thermodynamically stable structures with minimal resorption of 
bone in in vivo conditions; 
 Chemosorption of phosphates and diphosphonates onto the hydroxyapatite surface. 
Examples include 32P-orthophosphate and organophosphate compounds labelled with 
32P, 131I, and 211At; 
 Formation of bridging groups between ions of the radioactive metal and 
hydroxyapatite in the presence of multidentate phosphonate and carboxyl chelate 
complexes. By this mechanism, 186Re and 188Re-HEDP are sorbed. 
 
The location of phosphonate complexes in bone is explained by the chemical affinities of 
diphosphonic acids for calcium in growing bone tissue. It has been suggested that 
tetraphosphonates may have greater chemical affinity for bone tissue. Multidentate 
aminophosphate ligands form more stable chelate complexes than diphosphonate ligands [10]. 
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Figure 7. Tetraphosphonic acids: 1,4,7,10-tetraazacyclododecyl 
tetraaminotetramethylenephosphonic acid (a), dimethylpropylenediamine 
tetra(methylenephosphonic) acid (b). 
In literature, a stable complex with technetium-99m has been prepared using a multidentate 
phosphonate ligand Am-Bz-EDTMP (aminobenzyl ethylenediamine tetra(methyl phosphonic) 
acid). This complex showed best high bone uptake, low non -osseous uptake, and rapid blood 
clearance, which warranted its further investigation [32]. 
N N
H2O3P
H2O3P
PO3H2
PO3H2
NH2
 
Figure 8. Aminobenzyl ethylenediamine tetra(methylphosphonic) acid (Am-Bz-EDTMP). 
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3. Experimental part 
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3.1. General procedure 
Samples were measured on FT-IR spectrometer iS50, reflection ATR technique on diamond 
crystals. Spectra were measured in the mid-IR spectral region (MIR) from 4000 to 400 cm-1 
with a resolution of 2 cm-1, and further evaluated in the program Omnic 9.1. 
The NMR spectra were recorded on Bruker Avance II 300 ( 1H at 300,13 MHz and 13C 
at 75,45 MHz) in solution 2H2O. For 
1H NMR, dioxane was used as an internal standard. 
Chemical shifts of 13C NMR spectra were referenced relative to δ (dioxane) = 66,66 ppm. 
ESI mass spectra were recorded on Finnigan MAT SSQ 7000 in MeOH. The purity of the 
samples was monitored by TLC foils Kieselgel 60 F254 (Merck). Detection of the TLC sheet 
was performed by means of UV light (Model UVS 54, 254 nm). Products were dried on a 
vacuum line with the internal branch of a low-temperature cooler connected via a rotary oil 
pump LAVAT VRO 04/21 classic, bicameral pump. Other instruments were a centrifuge 
MPW Med Instruments, Model MPW-350, vibrational mixer VELP Scientific (P-LAB Inc.), a 
magnetic stirrer used with heating and IKAMAG rotavapor BUCHI R-215. Ultrapure water 
was prepared by apparatus Direct-Q3, water purification system MILLIPORE. For dispersion 
of samples, Branson Digital Sonifier and Elmasonic S 100 H ultrasonic bath were used. 
Activities of reaction mixtures were measured on a radioactivity detector with 
ionization chamber type CII CRC 55tW (CAPINTEC), a well type NaI(Tl) detector. The 
yields of labelled acids were determined by paper chromatography on Whatman 1 paper, by 
measuring the activity on Bioscan AR-2000 Radio-TLC Imaging Scanner (Canberra Packard) 
with P10 (argone-methane mixture) counting gas (Linde). 
Samples were filtered through PTFE (13 mm, 0,22 µm) syringe filters. 
 
3.1.1. Used chemicals 
In experiments, the following chemicals were used: methylenediphosphonic acid, etidronic 
acid and 95% pamidronate disodium salt hydrate (Sigma Aldrich), zoledronic acid (solution 
for infusion, Sandoz), concentrated HCl 37% p.a., isopropanol p.a., citric acid and ammonium 
hydroxide 25% p.a. from Lachner, tetrabutyl ortho titanate p.a. (Merck), SnCl2·2H2O from 
BDH LTD, NaCl (Chemapol), polyethylene glycol 4000 from Lachema and Dowex 50 WX 8 
(Serva). 
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3.2. Preparation and purification of phosphonic acids 
According to literature [33], phosphonic acids were prepared by the Mannich type reaction of 
an amine, formaldehyde and phosphorous acid according to the general equation (Scheme 1.), 
where 37% HCl was used as a catalyst.  
R
NH2
NH2
+ 4CH2O + 4H3PO4
5HCl
R
N
N
PO3H2
PO3H2
PO3H2
PO3H2
+ 4H2O
       
1) R= -CH2-CH2-
2) R= -CH2-CH2-CH2- 
3) R=
        
Scheme 1. Synthesis of compounds 1, 2 and 3. 
 
The compounds EDTMP (1), PDTMP (2) and CDTMP (3) were prepared as part of research 
project of M. Sakmár [34]. 
After synthesis, the phosphonic acids were purified by the method of ion excange 
chromatography (Dowex 50 WX8, H+ form, 200-400 mesh). Dowex ion excange resin was 
first washed with 1 mM HCl and then regenerated with 1 M HCl. The compound mixture was 
then eluted from the column using demmineralised water until pH reached a value of 4,5-6. 
The desired compound was eluted in the first fractions while the impurities remained on the 
column. 
Purified phosphonic acids were fully characterized by available spectral methods (NMR, MS, 
FT-IR). 
For mass spectra analysis, 1 mg of dried compound was dissolved in 1 mL of ultrapure 
water. Of that mixture, 100 µL was diluted in 1 mL of MeOH and used for analysis. To 
enhance the visibility of the molecular ion, 100 µL of 1% formic acid was added. 
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3.3. Preparation and labelling of nanocomposites with 99mTc 
Purified phosphonic acids EDTMP (1), PDTMP (2) and CDTMP (3), and commercially 
obtained methylenediphosphonic acid MDP (4), etidronic acid HEDP (5), zoledronic acid (6), 
pamidronic acid (7) and polyethylene glycol (8) were used for preparation and stabilisation of 
nanocomposites. 
Hydroxyapatite nanoparticles were prepared by P.Mičolová and E.Kukleva as 
described in literature [35], by mixing 25 mL of 0,8 M (NH4)2HPO3 and 25 mL of 1,34 M 
Ca(NO3)2. Before adding Ca(NO3)2, the pH value was adjusted to 9 by addition of NH4OH. 
The precipitated nanoparticles were centrifuged, washed with ultrapure water and dried under 
reduced pressure. 
Before labelling composite nanoparticles with 99mTc, a  fresh solution of SnCl2 was 
prepared by dissolving 13 mg SnCl2 in 25 mL of water and 0,5 mL of the prepared SnCl2 
solution was added to each sample for the reduction of  TcO4
- to 99mTc4+.  
A 99Mo/99mTc generator (Fig.9) was eluted and in each elution, 5-10 mL of 
physiological saline (0,9% NaCl) containing TcO4
-  was obtained. Due to the decay of 99Mo 
(T1/2=66 h), on the first day of using the generator, the most activity (2 GBq) could be 
obtained, while for elution up to 4 days later, less activity was obtained (800 MBq). The 
saline was distributed evenly, 150-250 MBq of activity for each sample. 
 
 
Figure 9. 99Mo/99mTc generator. 
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3.3.1. Preparation and labelling of stabilised nanocomposites 
Nanocomposites (9-13) were prepared by adding phosphonate ligands to 1,0 mg of prepared 
hydroxyapatite nanoparticles in 500 µL of ultrapure water. For stabilisation of nanoparticles, 
0,01 mg of citric or 10 µL of 0,1 M hydrochloric acid was added. The samples were first 
dispersed in ultrasound bath for 15 min and then by sonifier for 5 min. The maximal 
temperature for dispersion was set to 40ºC and the amplitude was 10%. The composition of 
the nanocomposites is shown in Table 3. 
Table 3. Composition of prepared samples. V(stock) is the volume of stock solution which 
containes 0,1 mg of phosphonate ligand. 
Sample Composite 
m(HAp) 
[mg] 
m(ligand) 
[mg] 
c(stock) 
[mmolmL-1] 
V(stock) 
[µL] 
9 MDP-HAp 1,0 0,1 0,014 41,9 
10 CDTMP-HAp 1,0 0,1 0,015 13,3 
11 HEDP-HAp 1,0 0,1 0,031 14,3 
12 PDTMP-HAp 1,0 0,1 0,010 21,8 
13 EDTMP-HAp 1,0 0,1 0,005 49,9 
 
Samples 14 and 15 were prepared as shown in Table 4. The samples were dispersed by 
sonifier for 3 min at 40°C and amplitude 10%. 
Table 4. Composition of nanocomposites with zoledronic and pamidronic acid. 
Sample Composite 
m(HAp) 
[mg] 
m(ligand) 
[mg] 
c(stock) 
[mgmL-1] 
V(stock) 
[mL] 
14 zoledronic acid-HAp 1,0 0,1 0,04 2,5 
15 pamidronic acid-HAp 1,0 0,1 1,00 0,1 
 
One, 2 and 4 mg/mL solutions of polyethylene glycol in 0,1 mL of isopropanol were 
prepared. Each solution was added to 1 mg of hydroxyapatite nanoparticles in 500 µL of 
ultrapure water (samples 16-18, Table 5). The samples were dispersed for 3 min (40°C, 10%). 
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Table 5. Composition of nanocomposites with different concentrations of polyethylene 
glycol. 
Sample Composite 
m(HAp) 
[mg] 
m(PEG) 
[mg] 
c(stock) 
[mgmL-1] 
V(stock) 
[mL] 
16 PEG-HAp 1,0 1,0 1,0 1,0 
17 PEG-HAp 1,0 2,0 2,0 1,0 
18 PEG-HAp 1,0 4,0 4,0 1,0 
 
To prepared samples (9-18), 150-250 MBq of activity was added and the activity of individual 
samples was measured. During incubation time of 1 h, samples were mixed on a vibratory 
shaker. After centrifugation at 4000 rpm for 5 min, the supernatant liquid was separated from 
the precipitate and its activity was measured. The precipitate was then washed 3 times with 1 
mL of physiological saline and the activity of the saline was measured each time. After the 
last wash, to determine the labelling yield, the activity of the remaining precipitate was 
measured. 
After the last wash, samples (16-18) were filtered through PTFE (13 mm, 0,22 µm) 
syringe filter and the activity of the filtrate was measured. 
 
3.3.2. Stabilisation of nanocomposites after labelling 
Samples (9-13) were prepared according to Table 3., and were not stabilised before labelling. 
For preparation of samples 19 and 20, 1 mg of hydroxyapatite nanoparticles in 500 µL of 
ultrapure water was dispersed for 3 min at 40°C and amplitude of 10%. Unstabilised 
nanoparticles were labelled and the labelling yield was determined after washing the 
nanoparticles 3 times, as described in chapter 3.3.1. 
For stabilisation of labelled nanoparticles, 0,01 mg of citric or 10 µL of 0,1 M hydrochloric 
(9-13); 0,1 mg of zoledronic (19) or pamidronic (20) acid was added. The samples were 
dispersed for 3 min at 40°C and amplitude of 10%. After dispergation, samples were filtered 
(PTFE 13 mm, 0,22 µm filter) and the activity of the filtrate was measured to determine the 
labelling yield of the complete procedure. 
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3.3.3. Preparation of nanocomposites after labelling  
Mass of 0,1 mg of zoledronic (21) and pamidronic (22) acid was labelled with 99mTc. 
The samples were heated for 30 min at 70°C. The labelling yields were determined by paper 
chromatography on Whatman 1 paper in physiological saline and MEK [36]. 1 mg of 
dispersed hydroxyapatite nanoparticles in 500 µL water was added to the labelled 
nanoparticles and the solution was dispersed again. After 30 min, the samples were washed 3 
times and measured to determine the labelling yield. 
 
3.3.4. Stabilisation of nanocomposites during their preparation  
Hydroxyapatite nanoparticles (23-27) were prepared by adding 0,07 mmol of phosphonate 
ligands (1-7) in 800 µL of water to 600 µL (NH4)2HPO4. Then 600 µL of Ca(NO3)2 was 
added and the mixture was dispersed. 
Nanoparticles of TiO2 (28-32) were prepared by adding 800 µL of a 0,07 mmol 
solution of phosphonate ligands (1-7) in ultrapure water, to 2 mL of ultrapure water. To the 
mixture was then added 2x575 µL of TBOT:IPA. The mixture of tetra n-butyl orthotitanate 
(TBOT) and isopropyl alcohol (IPA) was prepared in a ratio of 250 µL: 900 µL. The 
nanoparticles were formed by the proces of hydrolysis while being dispersed by sonifier. The 
operating conditions of the sonifier were 3 min, maximal temperature 40°C and amplitude 
30%.  
Prepared nanoparticles were then washed 2 times, with water and methanol, during 
which they were precipitated by centrifuge at 9000 rpm. The high number of rotations per 
minute was used due to the small particle size. 
Each sample of nanoparticles (23-32) was divided into 3 samples by taking 500 µL of 
dispersed nanoparticles. The samples were labelled and then washed 3 times to determine the 
labelling yield. 
 
3.4. Preparation and labelling of nanocomposites with 223Ra 
An 227Ac/227Th/223Ra generator (Fig.10) was eluted using a solution of 0,7 M HNO3 in 80% 
MeOH [37]. The eluent was evaporated on a rotary evaporator and 223Ra(NO)2 was 
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reconstituted in ultrapure water. To each sample, 2-4 µL of the solution was added so the 
starting activity for each sample would be approximately 7000 cps.  
 
Figure 10. 227Ac/227Th/223Ra generator. 
 
3.4.1. Preparation and labelling of stabilised nanocomposites 
Samples were prepared by adding 1µL (33, 34) or 15 µL (35, 36) of NH4OH to 0,1 mg of 
zoledronic (33, 35) and pamidronic (34, 36) acid, adding the solution to 1,0 mg of 
hydroxyapatite and dispersing the samples (3 min, 40°C, 10%). 
Approximately 2 µL of 223Ra solution was added and the activity of each sample was 
measured. After 30 min, the samples were washed 3 times and the labelling yield was 
calculated. 
 
3.4.2. Stabilisation of nanocomposites after labelling 
To the 1,0 mg of hydroxyapatite nanoparticles (37, 38) dispersed in 500 µL of water (3 min, 
40°C, 10%), 15 µL of NH4OH was added. 
For labelling, 2-4 µL of 223Ra was added and after 30 min of mixing, samples were 
washed 3 times and the remaining activity was measured. 10 µL of NH4OH was added to 0,1 
mg of zoledronic (37) and pamidronic (38) acid. The samples were then dispersed and after 1 
h of mixing, filtered through PTFE (13 mm, 0,22 µm) filter. 
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4. Results and discussion 
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4.1. Purification of compounds 
5,14 g of CDTMP was dissolved in 25 mL H2O and eluted through Dowex ion excange resin 
with 150 mL H2O. Mass of purified compound was 5,07 g (yield=98%). 
2,00 g of EDTMP was dissolved in 70 mL H2O and eluted through Dowex ion excange resin 
with 100 mL H2O. Mass of purified compound was 0,53 g (yield=26%). 
0,59 g of PDTMP was dissolved in 25 mL H2O and eluted through Dowex ion excange resin 
with 150 mL H2O. Mass of purified compound was 0,25 g (yield=42%). 
 
1)
N N
H2O3P
H2O3P
PO3H2
PO3H2           2)   
NN
H2O3P
H2O3P
PO3H2
PO3H2
 
 
Figure 11. Structures of compounds 1 and 2. 
3)
N N
H2O3P
H2O3P
PO3H2
PO3H2  
Figure 12. Compound 3. 
Spectra of purified compounds correspond to the spectra described in the literature [38]. 
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4.2. Preparation and labelling of nanocomposites with 99mTc 
Results of labelling nanocomposites with 99mTc are listed in Tables 6-15. Each sample was 
prepared in duplicate. 
Labelling yields were calculated according to equation  2. In equations 2 and 3, Aend is 
the activity of the precipitate after washing or activity of the filtrate after filtering. Acorr is 
the value of start activity (Astart), corrected according to time from the begining until the end 
of measurments (t/ min), due to the half-life of 99mTc (T=360 min). 
 
     𝑦𝑖𝑒𝑙𝑑 =
𝐴𝑒𝑛𝑑
𝐴𝑐𝑜𝑟𝑟
∙ 100     (2) 
                                                          𝐴𝑐𝑜𝑟𝑟 = 𝐴𝑠𝑡𝑎𝑟𝑡 ∙ 2
−
𝑡
𝑇    (3) 
 
4.2.1. Preparation and labelling of stabilised nanocomposites 
Nanoparticles have a particular tendency to lower their very high surface energy, which is the 
origin of their thermodynamic instability. Bare nanoparticles tend to stabilise themselves 
either by sorption of molecules from the surroundings or by lowering the surface area through 
coagulation and agglomeration. In order to avoid the later, nanoparticles have to be kinetically 
stabilized by electrostatic, steric, or electrosteric repulsive forces [39].  
Studies [10] led to the conclusion that the yield increases when the mean charge on 
MDP decreases so addition of citric or hydrochloric acid should increase the yields of 
labelling MDP as well as other phosphonate ligands because the chemical form of MDP 
(H4L) in aqueous solution depends on the pH, as follows: 
 
H4L ↔ H3L– ↔ H2L2– ↔ HL3– ↔ L4–                       (4) 
Decreases in pH (increases in the hydrogen ion concentration) displace the equilibrium to the 
left and decrease the mean charge of MDP.  
To electrostatically stabilise nanocomposites of HAp and compounds 1-5, citric 
(Table 6.) and hydrochloric (Table 7.) acid were added. 
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Figure 13. Methylenediphosphonic (4) and etidronic (5) acid. 
 
Table 6. Samples 9-13 stabilised with citric acid. Astart is the activity added to each sample, 
Aend activity of precipitate after 3 washes and Acorr corrected value of Astart. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
9 MDP 171 17 132 13 
9 MDP 175 10 135 7 
10 CDTMP 169 78 130 60 
10 CDTMP 181 115 139 83 
11 HEDP 184 14 142 10 
11 HEDP 184 30 139 21 
12 PDTMP 186 125 141 88 
12 PDTMP 175 71 132 54 
13 EDTMP 182 32 138 23 
13 EDTMP 182 35 137 25 
 
As shown in Table 6., the best labelling yields are obtained with ligands CDTMP and 
PDTMP. The yields of other samples are very low, most of the 99mTc was not bound to the 
nanoparticles and was washed away. 
Ligands EDTMP, PDTMP and CDTMP have two nitrogen atoms and four 
phosphonate groups (oxygen atoms) which are capable of coordinating to metal ions. On the 
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other hand, MDP and HEDP have two phosphonate groups and HEDP has one hydroxyl 
group. The number of coordinating atoms/groups in EDTMP, PDTMP and CDTMP is greater 
than that in MDP and HEDP so their complexes are more stable [40] and labelling yields for 
tetraphosphonates EDTMP, PDTMP and CDTMP were higher than for diphosphonates MDP 
and HEDP. 
When the same amount of hydrochloric as citric acid was added (0,01 mg), 
hydroxyapatite nanoparticles were dissolved. For that reason, a smaller amount of 
hydrochloric acid was used (10 µL of 0,1 M HCl). Too low pH value causes dissolving of 
hydroxyapatite nanoparticles, or their stabilisation at a too small size.  
The pH value can also effect the form of 99mTc. In a strong acidic condition, 99mTcO4
- 
is not completely reduced. On the contrary, when the pH value is larger than 6, Na99mTcO4 
will be easily changed into the colloid of 99mTc by SnCl2 under the alkaline condition, and 
therefore, the yield will decrease significantly. So, the best pH value for labelling with 99mTc 
is 4–6 [36].  
 
Table 7. Samples 9-13 stabilised with hydrochloric acid. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
9 
MDP 159 40 117 34 
9 MDP 169 18 123 15 
10 CDTMP 116 78 88 89 
10 CDTMP 132 86 99 86 
11 HEDP 164 15 120 12 
11 HEDP 190 69 139 50 
12 PDTMP 126 88 95 93 
12 PDTMP 134 95 102 93 
13 EDTMP 187 33 137 24 
13 EDTMP 155 18 114 16 
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Results obtained when nanoparticles were stabilised with HCl were better then with citric 
acid. The same as with citric acid, the best yields were obtainted for CDTMP and PDTMP 
which confirmes that tetraphosphonates make more stable complexes than diphosphonates. 
Samples 14 and 15 were prepared with zoledronic and pamidronic acid (Fig.14), 
diphosphonates that contain one hydroxyl group, an imidazole ring (6) or amino group (7) as 
groups for coordinating metal ions. 
6)   
N
N
PO3H2H2O3P
HO
      7)    
H2O3P PO3H2
OH
NH2
 
Figure 14. Structures of zoledronic (6) and pamidronic (7) acid. 
Table 8. Labelling yields of samples 14 and 15. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
14 
zoledronic acid 173 1 135 1 
14 zoledronic acid 178 1 140 1 
15 pamidronic acid 215 121 166 73 
15 pamidronic acid 225 142 174 82 
 
During the process of adsorption of phosphonates on HAp, charges of phosphonates and HAp 
change reamarkably, and the adsorption of phosphonates relaxes charges of HAp surface 
towards those of HAp crystal, and the HAp surface is stabilised [41]. 
The rapid uptake of intravenously injected particulate drug carriers by cells of 
the mononuclear phagocyte system (MPS) is the main limitation for drug targeting to other 
sites in the human body. Polyethylene glycol (PEG) polymers are at present the most popular 
materials to modify particulate surfaces in order to avoid recognition by cells of the MPS 
[42]. Nanoparticle surface properties can be modified by binding hydrophilic polyethylene 
glycol (PEG), which can enable them to overcome the RES capture, prolong their blood 
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circulation time and reduce their toxicity [3]. In literature [43], it was described that PEG is 
protonated in isopropanol and then adsorbed on the HAp nanoparticle surfaces, increasing 
their stability by an electrosteric stabilisation mechanism. 
O
OH
H
n  
Figure 15. Polyethylene glycol (8). 
Table 9. Stabilisation of nanoparticles with PEG. 
Sample 
γ(PEG) 
[mgL-1] 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr1 
[MBq] 
Yield1 
[%] 
Afiltrate 
[MBq] 
Acorr2 
[MBq] 
Yield2 
[%] 
16 
1 205 157 159 98 63 146 43 
16 1 200 152 155 98 58 143 41 
17 2 196 150 152 99 14 139 10 
17 2 210 160 163 98 55 148 37 
18 4 171 126 130 97 77 121 63 
18 4 212 155 161 96 77 150 51 
Yield after 1Washing 3 times, 2Filtering 
Nanoparticles stabilised with PEG show good labelling yields (>96%), but due to their large 
size compared to the porosity of the filter (0,22 µm), approximately half of the activity 
remained on the filter and a fraction with a narrow size distribution was obtained.  
 
 
4.2.2. Stabilisation of nanocomposites after labelling 
While adding acid stabilises the nanoparticles and prevents their aggregation, it also decreses 
the sorption of 99mTc on the nanoparticles. To lessen the effect of acid on the sorbtion of 
99mTc, acid was added to the nanoparticles after labelling. 
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Table 10. Samples 9-13 stabilised with citric acid after labelling. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr1 
[MBq] 
Yield1 
[%] 
Afiltrate 
[MBq] 
Acorr2 
[MBq] 
Yield2 
[%] 
9 
MDP 214 103 165 62 69 150 46 
9 MPD 218 79 168 47 56 152 37 
10 CDTMP 218 159 168 95 102 150 68 
10 CDTMP 219 160 169 95 108 151 72 
11 HEDP 177 13 145 9 7 117 6 
11 HEDP 172 22 141 15 12 114 10 
12 PDTMP 202 153 160 96 82 135 60 
12 PDTMP 199 148 157 94 77 131 58 
13 EDTMP 174 38 143 27 17 115 15 
13 EDTMP 180 27 148 18 14 119 12 
Yield after 1Washing 3 times, 2Filtering 
As when samples were stabilised before labelling, again samples with CDTMP (72%)  and 
PDTMP (60%) showed the best yields. For CDTMP, HEDP and PDTMP, better yields are 
obtained when the nanocomposites were stabilised before labelling, while for MDP and 
EDTMP, yields were better when stabilised after labelling.  
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Table 11. Samples 9-13 stabilised with hydrochloric acid after labelling. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield1 
[%] 
Afiltrate 
[MBq] 
Acorr2 
[MBq] 
Yield2 
[%] 
9 
MDP 183 48 143 33 32 122 26 
9 MDP 167 41 131 31 25 111 22 
10 CDTMP 164 111 128 87 72 108 67 
10 CDTMP 166 111 130 85 39 110 35 
11 HEDP 155 11 121 9 7 99 7 
11 HEDP 150 38 117 32 20 96 21 
12 PDTMP 209 155 165 94 90 136 66 
12 PDTMP 198 145 156 93 107 130 83 
13 EDTMP 145 42 113 37 23 92 25 
13 EDTMP 165 46 129 36 30 105 28 
Yield after 1Washing 3 times, 2Filtering 
 
Table 12. Hydroxyapatite nanoparticles stabilised with zoledronic and pamidronic acid after 
labelling. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield1 
[%] 
Afiltrate 
[MBq] 
Acorr2 
[MBq] 
Yield2 
[%] 
19 
zoledronic acid 214 168 177 95 133 168 79 
19 zoledronic acid 242 187 200 94 156 190 82 
20 pamidronic acid 223 172 173 100 84 158 53 
20 pamidronic acid 235 181 181 100 76 166 46 
Yield after 1Washing 3 times, 2Filtering 
Labelled nanoparticles of HAp show very good yields >94%) but after stabilisation, the yields 
decresed, to 82% for zoledronic and 53% for pamidronic acid.  
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4.2.3. Preparation of nanocomposites after labelling 
Yields of labelling zoledronic and pamidronic acid were measured by paper chromatography. 
When MEK was used as mobile phase, 99mTc-zoledronic acid remained at the start (Rf = 
0,008) and the yield was 83%. In saline, 99mTc-zoledronic acid moved with the front (Rf = 
0,969, yield=88%). In MEK, 99mTc-pamidronic acid had Rf = 0,000 and yield 100%, while in 
saline, the values were Rf = 0,001 and yield=100%.  
The labelled acids were added to HAp and for samples with zoledronic acid, none of the 
added activity bound to the nanoparticles. 
Table 13. Preparation of nanocomposites with labelled phosphonic acids. 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
21 
zoledronic acid 243 0 154 0 
21 zoledronic acid 249 0 158 0 
22 pamidronic acid 177 77 122 63 
22 pamidronic acid 186 65 128 51 
 
By comparing the results of labelling before and after stabilisation with zoledronic and 
pamidronic acid, and preparing nanocomposites after labelling, conclusions can be made 
concerning the competition between HAp and phosphonates for binding of metal ions. In the 
case of zoledronic acid, very low yields (0-1%) were obtained when labelling stabilised 
nanoparticles and when nanocomposites were prepared after labelling, which could mean that 
zoledronic acid has higher affinity for 99mTc than HAp does so all the activity was bound by 
zoledronic acid and was washed away instead of remaining on the precipitate. When HAp was 
first labelled with 99mTc, 99mTc remained bound to HAp even after zoledronic acid was added 
and a higher yield was obtained. In case of pamidronic acid, the best yields were obtained 
when labelling after stabilisation which colud mean that the competition is not as high as with 
zoledronic acid.  
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4.2.4. Stabilisation of nanocomposites during their preparation  
Phosphonate ligands were added during the preparation of nanoparticles (23-32). The highest 
yields were obtained for ligands MDP and HEDP. Very low yields were obtained for 
EDTMP, possibly due to the poor solubility of EDTMP in water.  
 
Table 14. Hydroxyapatite nanocomposites (23-27). 
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
23 
MDP 61 32 37 87 
23 MDP 37 19 21 92 
23 MDP 60 32 35 92 
24 CDTMP 56 19 34 57 
24 CDTMP 53 18 29 61 
24 CDTMP 58 24 34 72 
25 HEDP 43 23 26 89 
25 HEDP 62 32 34 93 
25 HEDP 116 51 67 76 
26 PDTMP 126 51 76 67 
26 PDTMP 44 16 24 65 
26 PDTMP 53 22 31 72 
27 EDTMP 58 1 35 2 
27 EDTMP 68 1 38 2 
27 EDTMP 62 1 36 4 
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Labelling of TiO2 nanoparticles (Table 15) showed very high yields, >90% for all samples. 
The TiO2 nanoparticles were formed by process of hydrolysis with phosphonates present in 
the solution and the nanocomposites were formed in a way that enabled binding of all the 
added 99mTc, regardless of the type of phosphonate used. 
 
Table 15. TiO2 nanocomposites (28-32).  
Sample Ligand 
Astart 
[MBq] 
Aend 
[MBq] 
Acorr 
[MBq] 
Yield 
[%] 
28 
MDP 57 33 34 98 
28 MDP 53 29 30 97 
28 MDP 71 40 39 101 
29 CDTMP 59 34 35 98 
29 CDTMP 70 37 39 95 
29 CDTMP 61 32 35 93 
30 HEDP 44 25 26 96 
30 HEDP 62 33 34 96 
30 HEDP 61 33 35 95 
31 PDTMP 55 32 32 99 
31 PDTMP 55 31 31 101 
31 PDTMP 59 33 33 99 
32 EDTMP 58 34 34 100 
32 EDTMP 56 31 31 100 
32 EDTMP 58 33 33 100 
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4.3. Preparation and labelling of nanocomposites with 223Ra 
Nanoparticles labelled with 223Ra were precipitated with ligands 6 and 7. Equation 5 was used 
for calculating labelling yields. Aend is the activity of the precipitate after washing or activity 
of the filtrate after filtering. The corrected value Acorr was caltulated according to equation 6 
for labelling of stabilised nanoparticles or equation 7 for nanocomposites that were stabilised 
after labelling. Due to the long half-life of 223Ra (11,4 days) and the short time of experiments 
(4 hours), Acorr was not corrected for the decay over time of the experiments, as with 
99mTc. 
     𝑦𝑖𝑒𝑙𝑑 =
𝐴𝑒𝑛𝑑
𝐴𝑐𝑜𝑟𝑟
∙ 100     (5) 
                                                   𝐴𝑐𝑜𝑟𝑟 = 𝐴𝑒𝑛𝑑 + 𝐴𝑠 + ∑ 𝐴𝑤𝑎𝑠ℎ    (6) 
   𝐴𝑐𝑜𝑟𝑟2 = 𝐴𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑒 + 𝐴𝑠 + ∑ 𝐴𝑤𝑎𝑠ℎ + 𝐴𝑓𝑖𝑙𝑡𝑒𝑟 + 𝐴𝑡𝑢𝑏𝑒              (7) 
4.3.1. Preparation and labelling of stabilised nanocomposites 
Hydroxyapatite is a good candidate for 223Ra labelling, since Ra/Ca analogy allows direct 
radium incorporation into the structure of nanoparticles or even its re-sorption together with 
daughter nuclei on the NPs surface [35]. 
Yields obtained for labelling with 223Ra are lower then for labelling with 99mTc. Due to 
nitric acid beeing added to the samples together with radium, pH of the solution of 
nanoparticles was too low which caused the nanoparticles to dissolve. To prevent 
nanoparticles from dissolving, more NH4OH was added (Table 17.) and the labelling yields 
were increased. 
Table 16. Labelling of samples 33 and 34 at pH=6. 
Sample Ligand 
Astart 
[cps] 
Aend 
[cps] 
Acorr 
[cps] 
Yield 
[%] 
33 
zoledronic acid 4383 1858 5137 36 
33 zoledronic acid 6308 951 7217 13 
34 pamidronic acid 8671 399 9030 4 
34 pamidronic acid 7628 171 7853 2 
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Table 17. Labelling of samples 35 and 36 at pH=9. 
Sample Ligand 
Astart 
[cps] 
Aend 
[cps] 
Acorr 
[cps] 
Yield 
[%] 
35 
zoledronic acid 4416 1044 5164 20 
35 zoledronic acid 7262 1378 8242 17 
36 pamidronic acid 3986 2237 4528 49 
36 pamidronic acid 7405 4646 8393 55 
 
 
 
4.3.2. Stabilisation of nanocomposites after labelling 
Table 18. Hydroxyapatite nanoparticles stabilised with phosphonic acids after labelling (37, 
38). 
Sample Ligand 
Astart 
[cps] 
Aend 
[cps] 
Acorr1 
[cps] 
Yield1 
[%] 
Afiltrate 
[cps] 
Acorr2 
[cps] 
Yield2 
[%] 
37 
zoledronic acid 7932 5206 7758 67 3082 5931 52 
37 zoledronic acid 7833 5743 7924 72 3817 6360 60 
38 pamidronic acid 5600 4338 5693 76 1350 3344 40 
38 pamidronic acid 9470 6517 9688 67 2987 7171 42 
Yield after 1Washing 3 times, 2Filtering 
Labelling of HAp nanoparticles with 223Ra gave lower yields than with 99mTc. When 
nanoparticles were stabilised before labelling, 223Ra-pamidronic acid-HAp showed better 
yields (55%) than 223Ra-zoledronic acid-HAp (20%), while in case of stabilisation of 
nanoparticles after labelling, better results were obtained for 223Ra-zoledronic acid-HAp 
(60%). Again as with labelling with 99mTc, there is a competition between phosphonate 
ligands and HAp for binding 223Ra. The higher affinity of zoledronic acid for 223Ra then HAp 
caused low yields when labelling stabilised nanoparticles. 
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5. Conclusions 
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Phosphonic acids EDTMP, PDTMP and CDTMP were purified by ion exchange 
chromatography. 
Composite nanoparticles were prepared by precipitating EDTMP, PDTMP, CDTMP and 
commercially obtained MDP, HEDP, zoledronic acid, pamidronic acid and PEG with 
hydroxyapatite and TiO2 nanoparticles. Prepared nanoparticles were labelled with 
99mTc and 
223Ra. 
Nanocomposites with MDP, HEDP, EDTMP, PDTMP and CDTMP were stabilised with 
citric and hydrochloric acid. The best results were obtained for ligands PDTMP (93%) and 
CDTMP (89%) stabilised with hydrochloric acid before labelling. 
For the CDTMP, HEDP and PDTMP, better yields are obtained when the nanocomposites 
were stabilised before labelling, while for MDP and EDTMP, yields were better when 
stabilised after labelling. 
Very low yields (0-1%) were obtained for labelling stabilised nanoparticles and when 
nanocomposites with zoledronic acid were prepared after labelling due to the competition 
between HAp and phosphonates for binding of 99mTc. In case of pamidronic acid, the best 
yields were obtained when labelling after stabilisation (82%). 
Nanoparticles stabilised with PEG showed good labelling yields (>96%), but due to their 
large size, a lot of activity remained on the filter during filtering. 
When phosphonates were added during the preparation of HAp nanoparticles, the highest 
yields were obtained for ligands MDP (92%) and HEDP (93%) and the lowest yields were 
obtained for EDTMP (4%). Labelling of TiO2 nanoparticles during their preparation showed 
very high yields, >90% for all samples. 
Labelling of HAp nanoparticles with 223Ra gave lower yields than with 99mTc. When 
nanoparticles were stabilised before labelling, composites with pamidronic acid showed better 
yields (55%) than with zoledronic acid (20%), while in case of stabilisation of nanoparticles 
after labelling, better results were obtained for samples with zoledronic acid (60%).  
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